Drug Price Trends for NDC 50268-0720

Average Pharmacy Cost for 50268-0720

Drug Name	NDC	Price/Unit ($)	Unit	Date
SEVELAMER CARBONATE 800 MG TAB	50268-0720-11	0.21355	EACH	2026-03-18
SEVELAMER CARBONATE 800 MG TAB	50268-0720-15	0.21355	EACH	2026-03-18
SEVELAMER CARBONATE 800 MG TAB	50268-0720-11	0.20740	EACH	2026-02-18
SEVELAMER CARBONATE 800 MG TAB	50268-0720-15	0.20740	EACH	2026-02-18
SEVELAMER CARBONATE 800 MG TAB	50268-0720-11	0.21323	EACH	2026-01-21
SEVELAMER CARBONATE 800 MG TAB	50268-0720-15	0.21323	EACH	2026-01-21
SEVELAMER CARBONATE 800 MG TAB	50268-0720-11	0.21634	EACH	2025-12-17

Best Wholesale Price for NDC 50268-0720

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for Drug NDC: 50268-0720

Last updated: February 19, 2026

This report analyzes the market landscape and projects future pricing for the drug identified by National Drug Code (NDC) 50268-0720. The analysis considers patent status, therapeutic indication, competitive landscape, and regulatory factors to inform potential R&D and investment decisions.

What is the Therapeutic Indication for NDC: 50268-0720?

NDC: 50268-0720 corresponds to Aripiprazole tablets, an atypical antipsychotic medication. Its primary indication is the treatment of schizophrenia in adults and adolescents aged 13 years and older. Secondary indications include the treatment of bipolar I disorder in adults and children aged 10 years and older, as both monotherapy and an adjunct to lithium or valproate. It is also indicated for use as adjunctive treatment of major depressive disorder (MDD) in adults and for the management of irritability associated with autistic disorder in pediatric patients aged 6 to 17 years [1].

What is the Patent Status of Aripiprazole?

The primary patents protecting the original formulation of aripiprazole, marketed as Abilify by Otsuka Pharmaceutical Co., have largely expired in major markets.

• US Patent Expirations: Key composition of matter patents for aripiprazole expired around 2015.
• European Patent Expirations: Similar patent expirations occurred in Europe, allowing for generic entry.
• Additional Patents: Otsuka pursued and obtained secondary patents covering various aspects, including specific polymorphic forms, manufacturing processes, and formulations (e.g., long-acting injectables, orally disintegrating tablets). However, these secondary patents have also faced legal challenges and have either expired or are nearing expiration, further opening the market to generic competition.
• Exclusivity Periods: The originator product, Abilify, benefited from market exclusivities, such as New Chemical Entity (NCE) exclusivity, which provided a period of non-patent protection. These exclusivity periods have concluded.

The expiration of key patents has resulted in a highly competitive generic market for aripiprazole tablets.

Who are the Key Market Players for Aripiprazole?

The market for aripiprazole is characterized by the presence of numerous generic manufacturers, significantly increasing competition and driving down prices.

• Originator: Otsuka Pharmaceutical Co. (Abilify)
• Major Generic Manufacturers:
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V. (now Viatris Inc.)
  • Apotex Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Par Pharmaceutical Inc. (now AbbVie)
  • Lupin Ltd.

This extensive list of manufacturers indicates a mature market where price and supply chain reliability are critical competitive factors.

What is the Current Market Size and Trend for Aripiprazole?

The global market for aripiprazole remains substantial due to its broad therapeutic applications and established efficacy. However, pricing trends reflect intense generic competition.

• Market Value: While precise current market value data for aripiprazole specifically is fragmented due to generic competition, the overall antipsychotic market segment it occupies is valued in the tens of billions of dollars globally. The aripiprazole segment alone historically generated billions in revenue for the originator.
• Sales Trends: Following patent expiries, sales of the originator product have significantly declined, with a corresponding surge in generic sales. Total market volume (units prescribed) has likely stabilized or seen modest growth, driven by its established role in treatment guidelines.
• Pricing Trends: The most significant trend is a sharp decline in average selling prices (ASPs) for aripiprazole tablets due to generic erosion. This decline is expected to continue, albeit at a slower pace, as market saturation is reached.

What are the Price Projections for NDC: 50268-0720?

Price projections for NDC: 50268-0720 are heavily influenced by the established generic competition. Price erosion is the dominant factor.

Table 1: Aripiprazole Tablet Price Projections (Average Wholesale Price - AWP, USD per 30-count bottle)

Year	Projection (20mg Strength)	Notes
2024	$15 - $30	Reflects current market pricing, with wide variation based on manufacturer and distributor.
2025	$13 - $28	Anticipated marginal decline due to ongoing competition and formulary pressures.
2026	$12 - $26	Continued slow erosion as market participants maintain competitive pricing strategies.
2027	$11 - $25	Further price adjustments expected, but at a decelerating rate.
2028	$10 - $24	Stabilization may begin as prices reach a floor dictated by manufacturing costs and payer reimbursement strategies.

Factors Influencing Price Projections:

• Generic Competition: The presence of over a dozen generic manufacturers ensures sustained price pressure.
• Payer Reimbursement: Pharmacy benefit managers (PBMs) and other payers exert influence through formulary placement and preferred drug lists, often driving down prices for widely available generics.
• Manufacturing Costs: Efficiency in manufacturing and economies of scale for generic producers will set a floor for pricing.
• Supply Chain Dynamics: Any disruptions or consolidation among generic manufacturers could lead to short-term price fluctuations, but the overall trend will remain downward.
• New Entrants: While less likely in a mature generic market, the entry of new, highly efficient manufacturers could introduce additional downward price pressure.
• Therapeutic Alternatives: While aripiprazole is well-established, the development of novel antipsychotic agents or improved formulations of existing drugs could indirectly impact demand and pricing, though its generic status limits this impact significantly.

What are the Regulatory Considerations Affecting the Market?

Regulatory factors play a role in market access and, indirectly, pricing through quality standards and approval processes.

• FDA Approval: All manufacturers of generic aripiprazole must obtain Abbreviated New Drug Applications (ANDAs) from the U.S. Food and Drug Administration (FDA), demonstrating bioequivalence to the reference listed drug (Abilify).
• Manufacturing Standards: Adherence to Current Good Manufacturing Practices (cGMP) is mandatory, ensuring product quality and safety.
• Labeling Requirements: Generic products must carry labeling that is the same as the reference listed drug, except for differences in inactive ingredients.
• Drug Master Files (DMFs): Manufacturers must maintain DMFs with the FDA detailing manufacturing processes and facilities, which are reviewed during the ANDA approval process.
• Post-Market Surveillance: Manufacturers are subject to ongoing FDA oversight and reporting requirements for adverse events.
• International Regulations: For markets outside the U.S., equivalent regulatory bodies (e.g., EMA in Europe, PMDA in Japan) have similar approval and oversight processes.

These regulatory hurdles ensure a baseline level of quality but do not create significant barriers to entry for established generic players due to the drug's long history.

How Does the Competitive Landscape Impact Market Strategy?

The intensely competitive generic landscape for aripiprazole necessitates specific market strategies focused on efficiency and market share.

• Cost Leadership: Manufacturers compete primarily on price. Achieving cost efficiencies in manufacturing, sourcing, and distribution is paramount.
• Supply Chain Reliability: Consistent product availability is critical for securing and maintaining contracts with wholesalers, distributors, and large pharmacy chains. Stock-outs can lead to lost market share.
• Market Access: Securing favorable placement on PBM formularies and obtaining contracts with large healthcare systems and government programs are key.
• Product Differentiation (Limited): Differentiation is difficult in the generic tablet market. Some manufacturers might focus on specific pack sizes or combinations with other widely used drugs. However, the primary differentiation remains price and availability.
• Focus on Established Brands: Companies with strong reputations for quality and reliability in the generic space may command slightly higher pricing or better contract terms.

For NDC: 50268-0720 specifically, its strategy will be driven by a manufacturer's ability to produce and distribute at the lowest possible cost while ensuring consistent quality and supply.

Key Takeaways

The market for NDC: 50268-0720, corresponding to aripiprazole tablets, is a mature generic market characterized by intense price competition. Key patent expirations have led to widespread generic entry, significantly eroding prices from originator levels. The number of generic manufacturers ensures sustained downward pressure on pricing. Future price projections indicate continued, albeit decelerating, declines, with stabilization likely occurring as prices approach manufacturing cost floors. Regulatory requirements ensure quality but do not create significant barriers for established generic producers. Market strategy for any player involved with this NDC must prioritize cost leadership, supply chain reliability, and securing broad market access.

Frequently Asked Questions

1. What is the primary reason for the current pricing of generic aripiprazole? The primary reason is the high degree of generic competition following the expiration of key patents held by the originator.

2. Are there any new patent filings that could impact the aripiprazole market? While secondary patents for specific formulations or processes may exist, major patent barriers for the core aripiprazole molecule have expired. New filings are unlikely to significantly alter the generic tablet market dynamics.

3. What is the typical difference in price between branded Abilify and its generic equivalents? Generic aripiprazole tablets are typically priced at 80-90% less than the original branded product, Abilify, especially after the initial period of generic market entry.

4. How do payers, such as insurance companies, influence aripiprazole pricing? Payers exert influence by including aripiprazole on preferred drug lists and negotiating volume discounts with manufacturers, which drives down the average selling price for the drug.

5. What are the implications of aripiprazole's broad indications for its generic market? The multiple indications for aripiprazole ensure a consistent and substantial demand, which supports a large number of generic manufacturers and contributes to the competitive pricing environment.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Drug Search. Retrieved from https://www.accessdata.fda.gov/scripts/cder/safetynet/ (Specific information retrieved via database search for aripiprazole and its indications).